Breakthrough Pain
23
3
4
12
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
13.0%
3 terminated out of 23 trials
80.0%
-6.5% vs benchmark
39%
9 trials in Phase 3/4
33%
4 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (23)
Programmed Intermittent Epidural Bolus Compared With Continuous Infusion in Multiparous Women
PIEB Compared With CEI on Breakthrough Pain in Nulliparous Women
Paediatric Breakthrough Pain Assessment
Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During Labour
Comparison of Regimens MPIB, CIPCEA, PCEA
Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement
A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy
Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain
Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients
Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy
Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units
Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent
Staccato Fentanyl Single and Multidose PK
Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment
Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis
An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray.
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain